KR20040002970A - 심장 세포에서 칼슘 채널의 활성 조절 방법 및 그것을위한 시약 - Google Patents

심장 세포에서 칼슘 채널의 활성 조절 방법 및 그것을위한 시약 Download PDF

Info

Publication number
KR20040002970A
KR20040002970A KR10-2003-7014989A KR20037014989A KR20040002970A KR 20040002970 A KR20040002970 A KR 20040002970A KR 20037014989 A KR20037014989 A KR 20037014989A KR 20040002970 A KR20040002970 A KR 20040002970A
Authority
KR
South Korea
Prior art keywords
lys
arg
ala
seq
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2003-7014989A
Other languages
English (en)
Korean (ko)
Inventor
덜헌티안젤라페이
캐사로토마르코지오바니
Original Assignee
디 오스트레일리언 내셔널 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디 오스트레일리언 내셔널 유니버시티 filed Critical 디 오스트레일리언 내셔널 유니버시티
Publication of KR20040002970A publication Critical patent/KR20040002970A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
KR10-2003-7014989A 2001-05-17 2002-05-17 심장 세포에서 칼슘 채널의 활성 조절 방법 및 그것을위한 시약 Withdrawn KR20040002970A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR5066A AUPR506601A0 (en) 2001-05-17 2001-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
AUPR5066 2001-05-17
PCT/AU2002/000608 WO2002092119A1 (en) 2001-05-17 2002-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor

Publications (1)

Publication Number Publication Date
KR20040002970A true KR20040002970A (ko) 2004-01-07

Family

ID=3829046

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7014989A Withdrawn KR20040002970A (ko) 2001-05-17 2002-05-17 심장 세포에서 칼슘 채널의 활성 조절 방법 및 그것을위한 시약

Country Status (11)

Country Link
US (1) US20050049198A1 (https=)
EP (1) EP1392344A4 (https=)
JP (1) JP2004535397A (https=)
KR (1) KR20040002970A (https=)
CN (1) CN1516596A (https=)
AU (1) AUPR506601A0 (https=)
BR (1) BR0210902A (https=)
CA (1) CA2446839A1 (https=)
NZ (1) NZ529940A (https=)
WO (1) WO2002092119A1 (https=)
ZA (1) ZA200309727B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5370969B2 (ja) * 2010-02-23 2013-12-18 国立大学法人金沢大学 心筋障害の検査方法
CN101812523B (zh) * 2010-04-09 2012-08-22 广州益善生物技术有限公司 Ryr1基因snp检测特异性引物、液相芯片和检测方法
CN109010799B (zh) * 2018-07-09 2021-07-06 沣潮医药科技（上海）有限公司 RyR2蛋白或RyR2重组蛋白在制备抗心力衰竭药物中的用途
CN109306011B (zh) * 2018-09-27 2021-08-03 中国人民解放军第二军医大学 靶向RyR2蛋白的胞内纳米抗体在制备抗心力衰竭药物中的用途
CN119876003B (zh) * 2025-01-21 2026-04-24 深圳大学 一种肌质网钙泵囊泡的分离纯化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691310A (en) * 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
DE4110785A1 (de) * 1991-04-04 1992-10-08 Bayer Ag Gewebe-spezifische humane neuronale calcium-kanal-subtypen und deren verwendung
AU1890092A (en) * 1991-04-18 1992-11-17 Indiana University Foundation Novel ester derivatives of ryanodine and dehydroryanodine
JP2003510257A (ja) * 1999-09-22 2003-03-18 コグネティックス・インコーポレイテッド カッパ−コノトキシンｐｖｉｉａの使用
GB0005124D0 (en) * 2000-03-03 2000-04-26 Cellpep Sa Maurocalcin,analogues thereof and their therapeutical uses
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome

Also Published As

Publication number Publication date
CN1516596A (zh) 2004-07-28
BR0210902A (pt) 2004-06-08
AUPR506601A0 (en) 2001-06-07
WO2002092119A1 (en) 2002-11-21
JP2004535397A (ja) 2004-11-25
EP1392344A4 (en) 2005-09-21
EP1392344A1 (en) 2004-03-03
ZA200309727B (en) 2005-08-01
US20050049198A1 (en) 2005-03-03
CA2446839A1 (en) 2002-11-21
NZ529940A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
US7186694B2 (en) Leptin-related peptides
US6172043B1 (en) Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides
CA2213229A1 (en) Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
JP2005508882A (ja) インスリン調節アミノペプチダーゼ（ｉｒａｐ）／アンギオテンシンｉｖ（ａｔ４）受容体活性の調節
US7208572B2 (en) Leptin-related peptides
Tensen et al. The Lymnaea cardioexcitatory peptide (LyCEP) receptor: a G-protein–coupled receptor for a novel member of the RFamide neuropeptide family
US12247246B2 (en) Identification of inhibitors of TcpC and TIR NADase activity
KR20040002970A (ko) 심장 세포에서 칼슘 채널의 활성 조절 방법 및 그것을위한 시약
KR20190137786A (ko) 뇌 오스테오칼신 수용체 및 인지 장애
JP2002507892A (ja) ヒト・アデニル酸シクラーゼのクローニングおよび特性評価
CA2234417A1 (en) Human serum glucocorticoid regulated kinase, a target for chronic renal disease
JP2000037191A (ja) ラット・カテプシンｋのポリヌクレオチドおよびポリペプチド配列
US7056735B2 (en) Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator)
US7683031B2 (en) Short peptides from the ‘2nd loop’ of 7 transmembrane receptor which selectively modulate signal transduction
Vitale et al. Exocytosis in single chromaffin cells: regulation by a secretory granule-associated Go protein
AU2002252850A1 (en) Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
Van Acker et al. IP3-mediated Ca2+ signals in human neuroblastoma SH-SY5Y cells with exogenous overexpression of type 3 IP3 receptor
JP4512273B2 (ja) 新規なぺプチド類
Muretta Regulated traffic of Glut4
US7846683B2 (en) Method for identifying agents which modulate cell growth or survival
US20040072275A1 (en) Interaction of NMDA receptor with protein tyrosine phosphatase
Hurst SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE
Grueter Ca2+/calmodulin-dependent protein kinase II regulates cardiac l-type Ca2+ channels via the beta subunit
Seikel Jr Modulation of the voltage gated potassium channel Kv4. 2 by two distinct auxiliary subunits
QUENCHING W-Pos268

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000